Analysts expect that Mustang Bio Inc (NASDAQ:MBIO) will announce earnings of ($0.27) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Mustang Bio’s earnings. The highest EPS estimate is ($0.26) and the lowest is ($0.28). Mustang Bio posted earnings per share of ($0.28) during the same quarter last year, which would indicate a positive year over year growth rate of 3.6%. The firm is scheduled to report its next earnings results on Tuesday, November 12th.
According to Zacks, analysts expect that Mustang Bio will report full-year earnings of ($1.14) per share for the current financial year, with EPS estimates ranging from ($1.18) to ($1.11). For the next fiscal year, analysts expect that the business will post earnings of ($1.11) per share, with EPS estimates ranging from ($1.33) to ($0.93). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Mustang Bio.
Mustang Bio (NASDAQ:MBIO) last issued its earnings results on Friday, August 9th. The company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.05).
Shares of MBIO stock remained flat at $$2.90 during trading hours on Thursday. 156,807 shares of the stock traded hands, compared to its average volume of 488,609. The company has a 50 day moving average of $3.84 and a 200 day moving average of $3.70. The company has a quick ratio of 13.10, a current ratio of 13.10 and a debt-to-equity ratio of 0.21. Mustang Bio has a 52 week low of $2.18 and a 52 week high of $10.20. The stock has a market cap of $117.31 million, a P/E ratio of -2.54 and a beta of 2.10.
Several hedge funds have recently modified their holdings of MBIO. FNY Investment Advisers LLC bought a new stake in shares of Mustang Bio during the second quarter worth $736,000. National Asset Management Inc. increased its position in shares of Mustang Bio by 31.0% during the second quarter. National Asset Management Inc. now owns 107,874 shares of the company’s stock worth $397,000 after acquiring an additional 25,549 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Mustang Bio by 94.2% during the second quarter. JPMorgan Chase & Co. now owns 7,646 shares of the company’s stock worth $27,000 after acquiring an additional 3,708 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Mustang Bio during the second quarter worth $364,000. Finally, Charles Schwab Investment Management Inc. grew its position in Mustang Bio by 60.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 70,414 shares of the company’s stock valued at $260,000 after purchasing an additional 26,635 shares in the last quarter. 26.90% of the stock is owned by institutional investors.
About Mustang Bio
Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Recommended Story: CBOE Russell 2000® Volatility Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.